Acrobiosystems Co.,Ltd. (SHE:301080)
China · Delayed Price · Currency is CNY 62.62
-0.03 (-0.05%)
At close: Jan 22, 2026
Revenue by Product
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
Recombinant Protein | 535.69M | Log In | Log In | Log In | Log In | Upgrade |
Recombinant Protein Growth | 17.35% | Log In | Log In | Log In | Log In | Upgrade |
Antibodies, Kits and Other Reagents | 79.79M | Log In | Log In | Log In | Log In | Upgrade |
Antibodies, Kits and Other Reagents Growth | 31.23% | Log In | Log In | Log In | Log In | Upgrade |
Testing Services | 17.45M | Log In | Log In | Log In | Log In | Upgrade |
Testing Services Growth | 12.63% | Log In | Log In | Log In | Log In | Upgrade |
Other | 12.09M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 11.35% | Log In | Log In | Log In | Log In | Upgrade |
Non-New Coronavirus Anti-epidemic Products | - | Log In | Log In | Log In | Log In | Upgrade |
Non-New Coronavirus Anti-epidemic Products Growth | - | Log In | Log In | Log In | Log In | Upgrade |
New Coronavirus Anti-epidemic Products | - | Log In | Log In | Log In | Log In | Upgrade |
New Coronavirus Anti-epidemic Products - Recombinant Protein | - | Log In | Log In | Log In | Log In | Upgrade |
New Coronavirus Anti-epidemic Products - Antibody | - | Log In | Log In | Log In | Log In | Upgrade |
New Coronavirus Anti-epidemic Products - Reagent Test Kit | - | Log In | Log In | Log In | Log In | Upgrade |
Other | 12.09M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 11.35% | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Overseas | 428.67M | Log In | Log In | Log In | Log In | Upgrade |
Overseas Growth | 19.62% | Log In | Log In | Log In | Log In | Upgrade |
China | 216.36M | Log In | Log In | Log In | Log In | Upgrade |
China Growth | 16.76% | Log In | Log In | Log In | Log In | Upgrade |
United States | - | Log In | Log In | Log In | Log In | Upgrade |
United States Growth | - | Log In | Log In | Log In | Log In | Upgrade |
United Kingdom | - | Log In | Log In | Log In | Log In | Upgrade |
United Kingdom Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Japan | - | Log In | Log In | Log In | Log In | Upgrade |
Japan Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Asia-Pacific | - | Log In | Log In | Log In | Log In | Upgrade |
Asia-Pacific Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Europe | - | Log In | Log In | Log In | Log In | Upgrade |
Europe Growth | - | Log In | Log In | Log In | Log In | Upgrade |
South Korea | - | Log In | Log In | Log In | Log In | Upgrade |
South Korea Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Germany | - | Log In | Log In | Log In | Log In | Upgrade |
Germany Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Canada | - | Log In | Log In | Log In | Log In | Upgrade |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |